SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma reported Q1 2026 results with a net loss of $13.8 million ($0.69 per share), driven by increased R&D and G&A spend following its February IPO. The company holds $251 million in cash and short-term investments, providing a runway through 2028 to fund clinical development without near-term dilution risk. Topline 12-month data from the Phase 1/2 trial of its lead asset, the BIM-IOL System, showed 98% of patients eliminated topical eye drops and achieved a 34% mean reduction in intraocular pressure.
Key figures
- Revenue
- 0
- Net loss
- 13800000
- Rd expense
- 8500000
- G a expense
- 6900000
- Ipo proceeds
- 172500000
- Iop reduction pct
- 34
- Cash and investments
- 251000000
- Freedom from drops pct
- 98
- Weighted avg shares basic
- 19927848
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.